From gingival inflammation to bone loss, here's what veterinarians need to communicate to owners about periodontal disease.
Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA ...
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-m ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback